Clinical trial results:

A Phase II, Open-label, Multi-center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-term Follow-up

Summary

EudraCT number	2010-020925-42	
Trial protocol	AT FR DE BE PL CZ IT	
Global end of trial date		
Results information		
Result version number	v1 (current)	
This version publication date	19 May 2017	
First version publication date	19 May 2017	

Trial information

Trial identification

Sponsor protocol code	PMR-EC-1206
Additional study identifiers	
ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01294020
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Astellas Pharma Europe, Ltd
Sponsor organisation address	2000 Hillswood Drive, Chertsey Surrey, United Kingdom, KT16 0RS
Public contact	Clinical Trial Disclosure, Astellas Pharma Europe, Ltd, astellas.resultsdisclosure.@astellas.com
Scientific contact	Clinical Trial Disclosure, Astellas Pharma Europe, Ltd, astellas.resultsdisclosure.@astellas.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Nataa	

Notes:

Results analysis stage	
Analysis stage	Interim
Date of interim/final analysis	28 October 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the steady state area under the plasma concentration-time curve from time 0 to time 24 hours (AUC0-24h) of tacrolimus for tacrolimus prolonged release (Advagraf) with that of tacrolimus (Prograf) in stable pediatric allograft recipients after 1:1 (mg:mg) conversion from Prograf to Advagraf.

Protection of trial subjects:

This clinical study was written, conducted and reported in accordance with the protocol, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines, and applicable local regulations, including the European Directive 2001/20/EC, on the protection of human rights, and with the ethical principles that have their origin in the Declaration of Helsinki. Astellas ensures that the use and disclosure of protected health information (PHI) obtained during a research study complies with the fed ral, national and/or regional legislation related to the privacy and protection of personal information.

Background therapy:

This study is composed of 3 parts: Part A (Pharmacokinetics), Part B (Long-term follow-up) and Part C (Continuation of long-term follow-up until participants discontinued treatment or received the approved treatment). After enrollment, participants entered a 30-day screening period in Part A of the study during which time they were maintained on their routine twice daily tacrolimus (commercial Prograf) based immunosuppressive regimen, as determined by the Investigator and as supplied by the local hospital pharmacy.

Evidence for comparator: -	
Actual start date of recruitment	25 May 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	10 Years
Independent data monitoring committee (IDMC) involvement?	Yes
N	

Notes:

Population of trial subjects

Subjects enrolled per country

, , ,	
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Czech Republic: 10
Country: Number of subjects enrolled	France: 22
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Italy: 4
Country: Number of subjects enrolled	Poland: 28
Country: Number of subjects enrolled	United Kingdom: 15
Worldwide total number of subjects	81
EEA total number of subjects	81

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37	0

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	35
Adolescents (12-17 years)	46
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Recruitment

Recruitment details:

Children aged 5 years to 16 years of age were enrolled in sites in 7 countries: Belgium, Czech Republic, Germany, France, Italy, Poland and UK for this 3-part study. Results reported in this disclosure include data from Part A and Part B of the study.

Pre-assignment

Screening details:

Stable pediatric allograft recipients (children who previously received a single organ liver, kidney, heart, lung or intestinal transplantation [\geq 6 months post-transplant]) being treated with a tacrolimus based immunosuppressive regimen (\leq 3 months) who consented to enter this study and fulfilled all the eligibility criteria were enrolled.

Period 1	
Period 1 title	Part A: Pharmacokinetics
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded
Arms	

Arm title	Tacrolimus Prolonged Release (Part A)

Arm description:

Participants converted from their routine tacrolimus based immunosuppressive regimen to tacrolimus as a study medication twice daily on day 1 and continued to receive treatment up to day 7. On day 8, participants switched to tacrolimus prolonged release once daily and received treatment up to day 14 in Part A of the study.

Arm type	Experimental
Investigational medicinal product name	Tacrolimus prolonged release
Investigational medicinal product code	FK506E
Other name	Advagraf, Astagraf XL, Graceptor, Prograf XL
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants received tacrolimus prolonged release (strengths of 0.5 mg, 1 mg, 3 mg, 5 mg) with the same daily dose (1:1, mg:mg) after being coverted from tacrolimus on day 8, with the dose maintained up to day 14 in Part A of the study. Tacrolimus prolonged release capsules were taken orally once daily only in the morning, on an empty stomach, or at least 1 hour before or 2 to 3 hours after a meal.

Investigational medicinal product name	Tacrolimus
Investigational medicinal product code	FK506
Other name	Prograf
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants received tacrolimus (strengths of 0.5 mg, 1 mg, 5 mg) with the same daily dose (1:1, mg:mg) as received during the 30-day screening period in Part A of the study. Tacrolimus capsules were taken orally twice daily, morning and evening, on an empty stomach or at least 1 hour before, or 2 to 3 hours after any meal.

Number of subjects in period 1	Tacrolimus Prolonged Release (Part A)
Started	81
Treated with study drug	81
Completed	78
Not completed	3
Adverse Event	1
Withdrawal of consent	1
Site staff could not cover the overnight visit	1

Period 2

Period 2 title	Part B: Long-Term Follow-up	
Is this the baseline period?	No	
Allocation method	Not applicable	
Blinding used	Not blinded	

Arms

Arm title	Tacrolimus Prolonged Release (Part B)
-----------	---------------------------------------

Arm description:

After Part A, participants continued to receive tacrolimus prolonged release once daily from day 15 up to the end of Part B of the study.

Arm type	Experimental
Investigational medicinal product name	Tacrolimus prolonged release
Investigational medicinal product code	FK506E
Other name	Advagraf, Astagraf XL, Graceptor, Prograf XL
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants continued to receive tacrolimus prolonged release (strengths of 0.5 mg, 1 mg, 3 mg, 5 mg) with the same daily dose (1:1, mg:mg) from day 15 up to the end of Part B of the study but could be adjusted on the basis of trough drug measurement results. Tacrolimus prolonged release capsules were taken orally once daily only in the morning, on an empty stomach, or at least 1 hour before or 2 to 3 hours after a meal.

Number of subjects in period 2	Tacrolimus Prolonged Release (Part B)
Started	78
Completed	76
Not completed	2
Adverse Event	2

Baseline characteristics

Reporting groups

Reporting group description:

Participants converted from their routine tacrolimus based immunosuppressive regimen to tacrolimus as a study medication twice daily on day 1 and continued to receive treatment up to day 7. On day 8, participants switched to tacrolimus prolonged release once daily and received treatment up to day 14 in Part A of the study.

Reporting group vM	receive olimus Prolonged Release (Part A)	Total
--------------------	--	-------

End points reporting groups		
Reporting group title	Tacrolimus Prolonged Release (Part A)	
Reporting group description:		
Participants converted from their routine tacrolimus based immunosuppressive regimen to tacrolimus as a study medication twice daily on day 1 and continued to receive treatment up to day 7. On day 8, participants switched to tacrolimus prolonged release once daily and received treatment up to day 14 in Part A of the study.		
Reporting group title	Tacrolimus Prolonged Release (Part B)	
Reporting group description:		
After Part A, participants continued to receive tacrolimus prolonged release once daily from day 15 up to the end of Part B of the study.		
Subject analysis set title	Tacrolimus (Part A)	
Subject analysis set type	Sub-group analysis	
Subject analysis set description:		

Participants in the pharmacokinetic analysis set who received tacrolimus twice daily on day 1 up to day 7 in Part A of the study.

Subject analysis set title	Tacrolimus Prolonged Release (Part A)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants in the pharmacokinetic analysis set who received tacrolimus prolonged release once daily from day 8 up to day 14 in Part A of the study.

Subject analysis set title	Tacrolimus Prolonged Release (Part A + B)
Subject analysis set type	Intention-to-treat

Subject analysis set description:

Participants received tacrolimus prolonged release once daily from day 8 up to day 14 in Part A, and once daily from day 15 up to end of Part B of the study.

Primary: Area Under the Plasma Concentration-time Curve from Time 0 to Time 24 Hours (AUC0-24h) for Tacrolimus and Tacrolimus Prolonged Release

Area Under the Plasma Concentration-time Curve from Time 0 End point title to Time 24 Hours (AUC0-24h) for Tacrolimus and Tacrolimus Prolonged Release

End point description:

The analysis population was the Pharmacokinetics Analysis Set (PKAS), which consisted of all participants who received at least 1 dose of study drug and who provided 2 complete pharmacokinetic profiles.

End point type

Primary

End point timeframe:

Day 7 (for tacrolimus) and day 14 (for tacrolimus prolonged release) at predose and 1, 2, 4, 6, 12, 13, 14, 16, 18 and 24 hours postdose

End point values	Tacrolimus (Part A)	Tacrolimus Prolonged Release (Part A)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	74	74	
Units: ng*h/mL			
geometric mean (geometric coefficient of variation)	159.133 (± 32.7)	153.8194 (± 29.3)	

Statistical analysis title AUC24 (steady-state systemic exposure) Comparison	kposure) Comparison
--	---------------------

Statistical analysis description:

The comparison of pharmacokinetic (PK) parameter AUC24 between tacrolimus and tacrolimus prolonged release was assessed with a mixed effects model on log-transformed PK parameters with treatment, organ transplant and age (continuous variable) at baseline as fixed effects and patient as random effect. The number of participants analyzed is calculated by the system and cannot be changed; actual N=74.

Comparison groups	Tacrolimus Prolonged Release (Part A) v Tacrolimus (Part A)
Number of subjects included in analysis	
Analysis specification	Pre-specified
Analysis type	other ^[1]
Parameter estimate	Geometric least squares (LS) mean ratio
Point estimate	96.66
Confidence interval	
level	90 %
sides	2-sided
lower limit	92.31
upper limit	101.22

Notes:

[1] - The difference of LS means of log-transformed PK parameters between tacrolimus and tacrolimus prolonged release and its 90% CI are back-transformed to the raw scale and are expressed as percentages.

Secondary: Maximum Concentration (Cmax) of Tacrolimus and Tacrolimus Prolonged Release

End point title	Maximum Concentration (Cmax) of Tacrolimus and Tacrolimus
	Prolonged Release

End point description:

The analysis population was the PKAS. This PK parameter was not assessed in the evening for the tacrolimus prolonged release arm as prespecified in the protocol and is denoted as "99999."

End point type	Secondary
End point timeframe:	

End point timeframe:

Day 7 (for tacrolimus) and day 14 (for tacrolimus prolonged release) at predose and 1, 2, 4, 6, 12, 13, 14, 16, 18 and 24 hours postdose

End point values	Tacrolimus (Part A)	Tacrolimus Prolonged Release (Part A)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	74	74	
Units: ng/mL			
geometric mean (geometric coefficient of variation)			

Morning	11.792 (± 44.1)	11.048 (± 38.9)	
Evening	8.198 (± 40)	99999 (± 99999)	

Statistical analysis title Cmax Comparison
--

Statistical analysis description:

The comparison of pharmacokinetic parameter Cmax between tacrolimus and tacrolimus prolonged release was assessed with a mixed effects model on log-transformed PK parameters with treatment, organ transplant and age (continuous variable) at baseline as fixed effects and patient as random effect. The number of participants analyzed is calculated by the system and cannot be changed; actual N=74.

Comparison groups	Tacrolimus (Part A) v Tacrolimus Prolonged Release (Part A)
Number of subjects included in analysis	148
Analysis specification	Pre-specified
Analysis type	other ^[2]
Parameter estimate	Geometric LS mean ratio
Point estimate	93.69
Confidence interval	
level	90 %
sides	2-sided
lower limit	87.07
upper limit	100.81

Notes:

[2] - The difference of LS means of log-transformed pharmacokinetic parameters between tacrolimus and tacrolimus prolonged release and its 90% CI are back-transformed to the raw scale and are expressed as percentages. Morning Cmax in tacrolimus group was used for comparison with Cmax for participants in tacrolimus prolonged release group.

Secondary: Trough Concentration (C12) for Tacrolimus

End point title	Trough Concentration (C12) for Tacrolimus
End point description:	
The analysis population was the PKAS.	
End point type	Secondary
End point timeframe:	
Day 7, 12 hours after dosing	

End point values	Tacrolimus (Part A)		
Subject group type	Subject analysis set		
Number of subjects analysed	69		
Units: ng/mL			
geometric mean (geometric coefficient of variation)	4.753 (± 36.2)		

Statistical analyses

Secondary: Trough Concentration (C24) for Tacrolimus and Tacrolimus Prolonged Release

End point title	Trough Concentration (C24) for Tacrolimus and Tacrolimus Prolonged Release
End point description:	
The analysis population was the PKAS.	
End point type	Secondary
End point timeframe:	
Days 7 and 14, 24 hours after dosing	

End point values	Tacrolimus (Part A)	Tacrolimus Prolonged Release (Part A)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	74	74	
Units: ng/mL			
geometric mean (geometric coefficient of variation)	4.955 (± 37.6)	4.479 (± 31.7)	

Statistical analyses

Statistical analysis title C24 Comparison

Statistical analysis description:

The comparison of pharmacokinetic parameter C24 between tacrolimus and tacrolimus prolonged release was assessed with a mixed effects model on log-transformed PK parameters with treatment, organ transplant and age (continuous variable) at baseline as fixed effects and patient as random effect. The number of participants analyzed is calculated by the system and cannot be changed; actual N=74.

Comparison groups	Tacrolimus (Part A) v Tacrolimus Prolonged Release (Part A)
Number of subjects included in analysis	148
Analysis specification	Pre-specified
Analysis type	other ^[3]
Parameter estimate	Geometric LS mean ratio
Point estimate	90.39
Confidence interval	
level	90 %
sides	2-sided
lower limit	85
upper limit	96.13

Notes:

[3] - The difference of LS means of log-transformed pharmacokinetic parameters between tacrolimus and tacrolimus prolonged release and its 90% CI are back-transformed to the raw scale and are expressed as percentages.

Secondary: Time to Attain Maximum Concentration (tmax) of Tacrolimus and Tacrolimus Prolonged Release

End point title

Time to Attain Maximum Concentration (tmax) of Tacrolimus and Tacrolimus Prolonged Release

End point description:

The analysis population was the PKAS. This PK parameter was not assessed in the evening for the tacrolimus prolonged release arm as prespecified in the protocol and is denoted as "99999."

End point type Secondary	End point type	Secondary
--------------------------	----------------	-----------

End point timeframe:

Day 7 (for tacrolimus) and day 14 (for tacrolimus prolonged release) at predose and 1, 2, 4, 6, 12, 13, 14, 16, 18 and 24 hours postdose

End point values	Tacrolimus (Part A)	Tacrolimus Prolonged Release (Part A)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	74	74	
Units: hours			
median (full range (min-max))			
Morning	1.0584 (0.9 to 6)	1.9833 (0.917 to 24)	
Evening	3.9667 (0 to 12)	99999 (99999 to 99999)	

Statistical analyses

No statistical analyses for this end point

End point title	Correlation between AUC24 and C24
End point description:	
The analysis population was the included in the analysis.	PKAS. Only participants with available C24 and AUC24 at each visit are
End point type	Secondary
End point timeframe:	
Day 7 (for tacrolimus) and day 1 14, 16, 18 and 24 hours postdos	4 (for tacrolimus prolonged release) at predose and 1, 2, 4, 6, 12, 13,

End point values	Tacrolimus (Part A)	Tacrolimus Prolonged Release (Part A)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	74	74	
Units: Pearson correlation coefficient			
number (not applicable)	0.84	0.89	

No statistical analyses for this end point

Secondary: Number of Participants with Acute Rejections

End point title

Number of Participants with Acute Rejections

End point description:

Rejection episodes/acute rejections were indicated by clinical and/or laboratory signs, and were classified according to their rejection specific treatment: •Spontaneously Resolving Acute Rejection: not treated with new or increased corticosteroid medication, antibodies or any other medication and resolved, irrespective of any tacrolimus dose changes; •Corticosteroid Sensitive Acute Rejection: treated with new or increased corticosteroid medication only and which has resolved, irrespective of any tacrolimus dose changes; •Corticosteroid: did not resolve following treatment with corticosteroids; - Resolved with further treatment: any acute rejection with an end date AND a treatment other than corticosteroid used; - Unresolved with further treatment: any acute rejection with no further treatment: any acute rejectio

End point type	Secondary
End point timeframe:	
Up to Week 54	

End point values	Tacrolimus Prolonged Release (Part A + B)		
Subject group type	Subject analysis set		
Number of subjects analysed	79		
Units: participants			
1. Any Acute Rejections	2		
1.a. Spontaneously Resolving Acute Rejection	0		
1.b. Corticosteroid Sensitive Acute Rejection	1		
1.c. Corticosteroid Resistant Acute Rejection	1		
1.c.1 Resolved with further treatment	1		
1.c.2 Unresolved with further treatment	0		
1.c.3 Unresolved with no further treatment	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Biopsy Proven Acute Rejections (BPARs)

-	Number of Participants with Biopsy Proven Acute Rejections
	(BPARs)

End point description:

BPAR episodes were defined as acute rejection episodes confirmed by biopsy, and were classified according to their rejection specific treatment: •Spontaneously Resolving Acute Rejection: not treated with new or increased corticosteroid medication, antibodies or any other medication and resolved, irrespective of any tacrolimus dose changes; •Corticosteroid Sensitive Acute Rejection: treated with new

or increased corticosteroid medication only and which has resolved, irrespective of any tacrolimus dose changes; •Corticosteroid Resistant Acute Rejection: did not resolve following treatment with corticosteroids; - Resolved with further treatment: any acute rejection with an end date AND a treatment other than corticosteroid used; - Unresolved with further treatment: any acute rejection with no further treatment other than corticosteroid used; - Unresolved with no further treatment: any acute rejection with no end date AND ONLY corticosteroid treatment used. mFAS.

End point type	Secondary
End point timeframe:	
Up to Week 54	

End point values	Tacrolimus Prolonged Release (Part A + B)		
Subject group type	Subject analysis set		
Number of subjects analysed	79		
Units: participants			
1. Biopsy proven acute rejections	1		
1.a. Spontaneously Resolving Acute Rejection	0		
1.b. Corticosteroid Sensitive Acute Rejection	0		
1.c. Corticosteroid Resistant Acute Rejection	1		
1.c.1 Resolved with further treatment	1		
1.c.2 Unresolved with further treatment	0		
1.c.3 Unresolved with no further treatment	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Severity of Biopsy Proven Acute Rejection Episodes

End point title	Severity of Biopsy Proven Acute Rejection Episodes

End point description:

The severity of BPARs was categorized with specific criteria by organ: For kidney transplant participants, according to Banff '97 Diagnostic categories for renal allograft biopsies – Banff '07 update (Acute antibody-mediated rejection I, II, and III, Acute T cell mediated rejection IA, IB, IIA, IIB and III); for liver transplant participants, according to 1997 Banff Schema for grading of Liver Allograft Rejection (mild, moderate, severe or indeterminate/borderline); for heart, according to Standardized Nomenclature of the International Society of Heart and Lung Transplantation (mild, moderate, severe). The analysis population was the modified Full Analysis Set (mFAS), which consisted of all participants who received at least 1 dose of tacrolimus prolonged release study drug.

End point type	Secondary
End point timeframe:	
Up to Week 54	

End point values	Tacrolimus Prolonged Release (Part A + B)		
Subject group type	Subject analysis set		
Number of subjects analysed	79		
Units: participants			
Kidney: Antibody-mediated rejection I	0		
Kidney: Antibody-mediated rejection II	1		
Kidney:Antibody-mediated rejection III	0		
Kidney:T cell mediated rejection IA	0		
Kidney:T cell mediated rejection IB	1		
Kidney:T cell mediated rejection IIA	0		
Kidney:T cell mediated rejection IIB	0		
Kidney:T cell mediated rejection III	0		
Liver: Mild	0		
Liver: Moderate	0		
Liver: Severe	0		
Liver: Indeterminate or borderline	0		
Heart: Mild	0		
Heart: Moderate	0		
Heart: Severe	0		

No statistical analyses for this end point

Secondary: Patient survival

End point title	Patient survival		
End point description:			
Patient survival was defined as the time from first dose of tacrolimus as study drug to the date of death			
from any cause. Since no participants died during the study, survival analysis was not conducted.			

nom any cause. Since no participants died during the study, survival analysis was not conducted.			
End point type Secondary			
End point timeframe:			
Up to Week 54			

End point values	Tacrolimus Prolonged Release (Part A + B)		
Subject group type	Subject analysis set		
Number of subjects analysed	0 ^[4]		
Units: days			
number (confidence interval 95%)	(to)		

Notes:

[4] - There were no deaths.

No statistical analyses for this end point

Secondary: Graft survival

End point t	itle
-------------	------

Graft survival

End point description:

Graft survival was defined as the time from the first dose of tacrolimus as study drug to graft loss. Graft loss was defined as retransplantation, nephrectomy (in case of kidney transplantation), death or dialysis (in case of kidney transplantation) ongoing at end of study or at discontinuation, unless superseded by follow-up information. Since no participants experienced graft loss during the study, survival analysis was not conducted.

End point type	Secondary
End point timeframe:	
Up to Week 54	

End point values	Tacrolimus Prolonged Release (Part A + B)		
Subject group type	Subject analysis set		
Number of subjects analysed	0 ^[5]		
Units: days			
number (confidence interval 95%)	(to)		

Notes:

[5] - There were no graft losses.

Statistical analyses

No statistical analyses for this end point

Secondary: Efficacy Failure				
End point title	Efficacy Failure			
End point description:				
Efficacy failure was defined as the composite of the following: death, graft loss, BPAR and unknown outcome. A participant was considered to have an unknown outcome if he/she did not have the event of				

interest (death, graft loss, BPAR) or did not have a study assessment prior to day 335. The analysis population was the mFAS.

End point type	Secondary
End point timeframe:	
Up to Week 54	

End point values	Tacrolimus Prolonged Release (Part A + B)		
Subject group type	Subject analysis set		
Number of subjects analysed	79		
Units: participants	3		

No statistical analyses for this end point

Secondary: Number of Participants with Adverse Events (Part A)

End point title Number of Participants with Adverse Events (Part A)

End point description:

Safety as assessed by adverse events (AEs), which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A serious AE (SAE) was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. The analysis population was the Full Analysis Set (FAS), which consisted of all participants who received at least 1 dose of any of the study drug (tacrolimus/tacrolimus prolonged release).

 End point type
 Secondary

 End point timeframe:
 End point timeframe is Dettained in the secondary

From first dose of tacrolimus up to 7 days after last dose of tacrolimus prolonged release in Part A (up to 21 days)

End point values	Tacrolimus (Part A)	Tacrolimus Prolonged Release (Part A)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	81	79	
Units: participants			
AEs	8	14	
Drug-related AEs	1	2	
Deaths	0	0	
SAEs	0	0	
Drug-related SAEs	0	0	
Deaths Resulting from AEs	0	0	
AEs Leading to Permanent Discontinuation	0	0	
Drug-related AEs Leading to Permanent Discont.	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Adverse Events (Part B)

End	point	title
-----	-------	-------

End point description:

Safety as assessed by adverse events (AEs), which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A serious AE (SAE) was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. The analysis population was the mFAS.

|--|

End point timeframe:

From first dose of tacrolimus prolonged release in Part A up to 7 days after last dose of tacrolimus prolonged release in Part B (up to 55 weeks)

End point values	Tacrolimus Prolonged Release (Part A + B)		
Subject group type	Subject analysis set		
Number of subjects analysed	79		
Units: participants			
AEs	67		
Drug-related AEs	28		
Deaths	0		
SAEs	19		
Drug-related SAEs	10		
Deaths Resulting from AEs	0		
AEs Leading to Permanent Discontinuation	1		
Drug-related AEs Leading to Permanent Discont.	1		

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug (tacrolimus/tacrolimus prolonged release) in Part A up to last dose of study drug (tacrolimus prolonged release) in Part B of the study

Assessment type	Systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	11.1
Reporting groups	
Reporting group title	Tacrolimus

Reporting group description:

Participants converted from their routine tacrolimus based immunosuppressive regimen to tacrolimus as a study medication twice daily on day 1 and continued to receive treatment up to day 7 in Part A of the study.

Reporting group title	Tacrolimus prolonged release

Reporting group description:

Participants switched to tacrolimus prolonged release once daily on day 8 and received treatment up to day 14 in Part A and continued to receive tacrolimus prolonged release once daily from day 15 up to the end of Part B of the study.

Serious adverse events	Tacrolimus	Tacrolimus prolonged release	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 81 (0.00%)	19 / 79 (24.05%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immunosuppressant drug level increased			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	1/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications Expired drug administered			
		I	I

subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Arteriovenous fistula operation			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Benign intracranial hypertension			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Drug interaction			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	1/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	1/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	1/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0/1	
deaths causally related to			
treatment / all	0 / 0	0 / 0	

subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
lepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	1/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal lisorders			
Lung disorder			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	1/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillar haemorrhage			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	0/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
nfections and infestations			
Cytomegalovirus infection			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences causally related to treatment / all	0 / 0	1/1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			I

subjects affected (expected		
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)
occurrences causally related to treatment / all	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis		
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)
occurrences causally related to treatment / all	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Liver abscess		
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences causally related to treatment / all	0 / 0	1/1
deaths causally related to treatment / all	0 / 0	0 / 0
Oral herpes		
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences causally related to treatment / all	0 / 0	1/1
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia		
subjects affected / exposed	0 / 81 (0.00%)	3 / 79 (3.80%)
occurrences causally related to treatment / all	0 / 0	1/3
deaths causally related to treatment / all	0 / 0	0 / 0
Superinfection bacterial		
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences causally related to treatment / all	0 / 0	1/1
deaths causally related to treatment / all	0 / 0	0 / 0
Viral infection		
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences causally related to treatment / all	0/0	0/1
deaths causally related to treatment / all	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Tacrolimus	Tacrolimus prolonged release	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 81 (9.88%)	66 / 79 (83.54%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Melanocytic naevus			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Skin papilloma			
subjects affected / exposed	0 / 81 (0.00%)	4 / 79 (5.06%)	
occurrences (all)	0	4	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Phlebitis			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Vena cava thrombosis			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Surgical and medical procedures			
Dermabrasion			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Enanthema			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Fatigue			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
Influenza like illness			

subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Injection site pain			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Malaise			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Pain			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Pyrexia			
subjects affected / exposed	0 / 81 (0.00%)	6 / 79 (7.59%)	
occurrences (all)	0	8	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal			
disorders Asthma			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
	0	2	
Cough			
subjects affected / exposed	0 / 81 (0.00%)	9 / 79 (11.39%)	
occurrences (all)	0	9	
Oropharyngeal pain			
subjects affected / exposed	0 / 81 (0.00%)	5 / 79 (6.33%)	
occurrences (all)	0	5	
Pharyngeal oedema			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Rhinitis allergic			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Psychiatric disorders			

subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Agitation subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Anxiety subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Insomnia subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Investigations Asportate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood trigtycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood trigtycerides increased subjects affected / exposed occurrences (all)	Abnormal behaviour			
occurrences (all)01Agitation subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Anxiety subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Insomnia subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1		0 / 81 (0.00%)	1 / 79 (1.27%)	
Agitation subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Anxiety subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Insomnia subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Investigations Asportate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affecte	occurrences (all)			
subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 1 / 79 (1.27%) Anxiety subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 1 / 79 (1.27%) Insomnia subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 1 / 79 (1.27%) Mood altered subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 1 / 79 (1.27%) Aspartate aminotransferase increased subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 1 / 79 (1.27%) Alanine aminotransferase increased subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 1 / 79 (1.27%) Blood creatinine increased subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 6 / 79 (7.59%) Blood iron decreased subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 3 / 79 (3.80%) 0 / 81 (0.00%) 1 / 79 (1.27%) 3 0 occurrences (all) 0 3 Blood iron decreased subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 1 / 79 (1.27%) 0 1 1 / 79 (1.27%) 1 Blood trighycerides increased subjects affected / exposed occurrences (all) 0 / 81 (0.00%) 1 / 79 (1.27%) 0 1 / 79 (1.27%) 1		C C	-	
occurrences (all)01Anxiety subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Insomnia subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)6 / 79 (7.59%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%)3 / 79 (3.80%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 0	-			
Anxiety subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Insomnia subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0	subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Insomnia subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (3.80%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0	occurrences (all)	0	1	
subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Insomnia subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (3.80%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0	Anxiety			
Insomnia subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0	subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 06 / 79 (7.59%) 6Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0	occurrences (all)	0	1	
subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 3Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1	Insomnia			
occurrences (all)01Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 06 / 79 (7.59%) 6Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0		0 / 81 (0 00%)	1 / 79 (1 27%)	
Mood altered subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 06 / 79 (7.59%) 6Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 3Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1				
subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 0Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 06 / 79 (7.59%) 6Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 0Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1		0	L	
occurrences (all)01InvestigationsAspartate aminotransferase increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Alanine aminotransferase increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)02Blood creatinine increased subjects affected / exposed0 / 81 (0.00%)6 / 79 (7.59%)occurrences (all)06Blood iron decreased subjects affected / exposed0 / 81 (0.00%)3 / 79 (3.80%)occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01	Mood altered			
InvestigationsAspartate aminotransferase increasedsubjects affected / exposedoccurrences (all)Alanine aminotransferase increased subjects affected / exposedoccurrences (all)Alanine aminotransferase increased subjects affected / exposedoccurrences (all)occurrences (all)01Blood creatinine increased subjects affected / exposed0 / 81 (0.00%)occurrences (all)006Blood iron decreased subjects affected / exposed0 / 81 (0.00%)occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01	subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
Aspertate aminotransferase increased0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Alanine aminotransferase increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)02Blood creatinine increased subjects affected / exposed0 / 81 (0.00%)6 / 79 (7.59%)occurrences (all)06Blood iron decreased subjects affected / exposed0 / 81 (0.00%)3 / 79 (3.80%)occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01	occurrences (all)	0	1	
Aspertate aminotransferase increased0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Alanine aminotransferase increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)02Blood creatinine increased subjects affected / exposed0 / 81 (0.00%)6 / 79 (7.59%)occurrences (all)06Blood iron decreased subjects affected / exposed0 / 81 (0.00%)3 / 79 (3.80%)occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01	Investigations			
occurrences (all)01Alanine aminotransferase increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)02Blood creatinine increased subjects affected / exposed0 / 81 (0.00%)6 / 79 (7.59%)occurrences (all)06Blood iron decreased subjects affected / exposed0 / 81 (0.00%)3 / 79 (3.80%)occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01	Aspartate aminotransferase			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 06 / 79 (7.59%) 6Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 3Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1	subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 2Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 66 / 79 (7.59%) 6Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 3Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 11 / 79 (1.27%) 1	occurrences (all)	0	1	
subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)02Blood creatinine increased subjects affected / exposed0 / 81 (0.00%)6 / 79 (7.59%)occurrences (all)06Blood iron decreased subjects affected / exposed0 / 81 (0.00%)3 / 79 (3.80%)occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01	Alanine aminotransferase increased			
occurrences (all)02Blood creatinine increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 06 / 79 (7.59%) 6Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 3Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1		0 / 81 (0 00%)	1 / 70 (1 27%)	
Blood creatinine increased subjects affected / exposed0 / 81 (0.00%)6 / 79 (7.59%)occurrences (all)06Blood iron decreased subjects affected / exposed0 / 81 (0.00%)3 / 79 (3.80%)occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01				
subjects affected / exposed occurrences (all)0 / 81 (0.00%) 06 / 79 (7.59%) 6Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 3Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 11 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 11 / 79 (1.27%) 1		0	2	
occurrences (all)06Blood iron decreased subjects affected / exposed0 / 81 (0.00%)3 / 79 (3.80%)occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01	Blood creatinine increased			
Blood iron decreased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 03 / 79 (3.80%) 3Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 01 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 11 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%) 11 / 79 (1.27%) 1	subjects affected / exposed	0 / 81 (0.00%)	6 / 79 (7.59%)	
subjects affected / exposed occurrences (all)0 / 81 (0.00%)3 / 79 (3.80%) 3Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 1	occurrences (all)	0	6	
subjects affected / exposed occurrences (all)0 / 81 (0.00%)3 / 79 (3.80%) 3Blood pressure increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 1Blood triglycerides increased subjects affected / exposed occurrences (all)0 / 81 (0.00%)1 / 79 (1.27%) 1	Blood iron decreased			
occurrences (all)03Blood pressure increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01		0 / 81 (0.00%)	3 / 79 (3.80%)	
subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01				
subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01				
occurrences (all)01Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01				
Blood triglycerides increased subjects affected / exposed0 / 81 (0.00%)1 / 79 (1.27%)occurrences (all)01		0 / 81 (0.00%)	1 / 79 (1.27%)	
subjects affected / exposed 0 / 81 (0.00%) 1 / 79 (1.27%) occurrences (all) 0 1	occurrences (all)	0	1	
subjects affected / exposed 0 / 81 (0.00%) 1 / 79 (1.27%) occurrences (all) 0 1	Blood triglycerides increased			
	subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
C-reactive protein increased	occurrences (all)	0		
	C-reactive protein increased			

subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
		-	
Immunosuppressant drug level decreased			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
International normalised ratio increased			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Vitamin D decreased			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
ζ,		-	
Weight decreased			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
njury, poisoning and procedural			
omplications Chronic allograft nephropathy			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)			
	0	2	
Contusion			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Drug dispensing error			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Drug dose omission			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Expired drug administered			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
laint arrain			
Joint sprain subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)			
	0	1	

occurrences (all) Nervous system disorders Clonus subjects affected / exposed occurrences (all) Dizziness subjects affected / exposed occurrences (all) Dizziness subjects affected / exposed occurrences (all) Epilepsy subjects affected / exposed occurrences (all) Headache subjects affected / exposed occurrences (all) Loss of consciousness subjects affected / exposed occurrences (all) Migraine subjects affected / exposed occurrences (all) Migraine subjects affected / exposed occurrences (all) Syncope vasovagal subjects affected / exposed occurrences (all) Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	/ 81 (0.00%) 0 / 81 (0.00%) 0 / 81 (0.00%) 0 / 81 (0.00%) 2 / 81 (0.00%) 0 / 81 (0.00%) 0	1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 11 / 79 (1.27%) 1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1	
Iervous system disorders 0 Clonus subjects affected / exposed 0 occurrences (all) 0 Dizziness subjects affected / exposed 0 occurrences (all) 0 Epilepsy subjects affected / exposed 0 occurrences (all) 0 Headache subjects affected / exposed 0 occurrences (all) 2 Loss of consciousness 0 subjects affected / exposed 0 occurrences (all) 0 Migraine 0 subjects affected / exposed 0 occurrences (all) 0 Migraine 0 subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0	/ 81 (0.00%) 0 / 81 (0.00%) 0 / 81 (0.00%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 11 / 79 (1.27%) 1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1	
Clonus subjects affected / exposed occurrences (all)0Dizziness subjects affected / exposed occurrences (all)0Epilepsy subjects affected / exposed occurrences (all)0Headache subjects affected / exposed occurrences (all)2Loss of consciousness subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0	0 / 81 (0.00%) 0 / 81 (0.00%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
subjects affected / exposed occurrences (all)0Dizziness subjects affected / exposed occurrences (all)0Epilepsy subjects affected / exposed occurrences (all)0Headache subjects affected / exposed occurrences (all)2Loss of consciousness subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0	0 / 81 (0.00%) 0 / 81 (0.00%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
occurrences (all)Dizziness subjects affected / exposed occurrences (all)0Epilepsy subjects affected / exposed occurrences (all)0Headache subjects affected / exposed occurrences (all)2Loss of consciousness subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0	0 / 81 (0.00%) 0 / 81 (0.00%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
Dizziness 0 subjects affected / exposed 0 occurrences (all) 0 Epilepsy 0 subjects affected / exposed 0 occurrences (all) 0 Headache 2 subjects affected / exposed 2 occurrences (all) 0 Loss of consciousness 0 subjects affected / exposed 0 occurrences (all) 0 Migraine 0 subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0 Blood and lymphatic system disorders Anaemia subjects affected / exposed 0	/ 81 (0.00%) 0 / 81 (0.00%) 0 / 81 (2.47%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 / 79 (1.27%) 1 1 / 79 (1.27%) 1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
subjects affected / exposed occurrences (all)0Epilepsy subjects affected / exposed occurrences (all)0Headache subjects affected / exposed occurrences (all)2Loss of consciousness subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0	0 / 81 (0.00%) 0 / 81 (2.47%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 1 / 79 (1.27%) 1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
occurrences (all)Epilepsy subjects affected / exposed occurrences (all)0Headache subjects affected / exposed occurrences (all)2Loss of consciousness subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0	0 / 81 (0.00%) 0 / 81 (2.47%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 1 / 79 (1.27%) 1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
Epilepsy subjects affected / exposed occurrences (all)0Headache subjects affected / exposed2occurrences (all)2Loss of consciousness subjects affected / exposed0occurrences (all)0Migraine subjects affected / exposed0occurrences (all)0Syncope vasovagal subjects affected / exposed0Syncope vasovagal subjects affected / exposed0Syncope vasovagal subjects affected / exposed0Sodd and lymphatic system disorders Anaemia subjects affected / exposed0	/ 81 (0.00%) 0 / 81 (2.47%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 / 79 (1.27%) 1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
subjects affected / exposed occurrences (all)0Headache subjects affected / exposed occurrences (all)2Loss of consciousness subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0	0 / 81 (2.47%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
subjects affected / exposed occurrences (all)0Headache subjects affected / exposed occurrences (all)2Loss of consciousness subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0	0 / 81 (2.47%) 2 / 81 (0.00%) 0 / 81 (0.00%)	1 11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
Headache 2 subjects affected / exposed 2 occurrences (all) 0 Loss of consciousness 0 subjects affected / exposed 0 occurrences (all) 0 Migraine 0 subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0 Solood and lymphatic system disorders 0 Anaemia 0 subjects affected / exposed 0	/ 81 (2.47%) 2 / 81 (0.00%) 0 / 81 (0.00%)	11 / 79 (13.92%) 14 1 / 79 (1.27%) 1	
subjects affected / exposed occurrences (all)2Loss of consciousness subjects affected / exposed occurrences (all)0Migraine subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Syncope vasovagal subjects affected / exposed occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed oc0	2 / 81 (0.00%) 0 / 81 (0.00%)	14 1 / 79 (1.27%) 1	
occurrences (all) Loss of consciousness 0 Loss of consciousness subjects affected / exposed 0 occurrences (all) Migraine 0 Migraine subjects affected / exposed 0 occurrences (all) 0 0 Syncope vasovagal 0 0 subjects affected / exposed 0 0 occurrences (all) 0 0 Slood and lymphatic system disorders 0 0 Anaemia subjects affected / exposed 0	2 / 81 (0.00%) 0 / 81 (0.00%)	14 1 / 79 (1.27%) 1	
Loss of consciousness subjects affected / exposed 0 occurrences (all) Migraine subjects affected / exposed 0 occurrences (all) Syncope vasovagal subjects affected / exposed 0 occurrences (all) Blood and lymphatic system disorders Anaemia subjects affected / exposed 0	/ 81 (0.00%) 0 / 81 (0.00%)	1 / 79 (1.27%) 1	
subjects affected / exposed0occurrences (all)0Migraine subjects affected / exposed0occurrences (all)0Syncope vasovagal subjects affected / exposed0occurrences (all)0Blood and lymphatic system disorders Anaemia subjects affected / exposed0occurrences (all)0	0 / 81 (0.00%)	1	
occurrences (all) Migraine 0 Migraine 0 0 subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0 Blood and lymphatic system disorders 0 Anaemia 0 subjects affected / exposed 0	0 / 81 (0.00%)	1	
Migraine 0 subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0 Blood and lymphatic system disorders Anaemia subjects affected / exposed 0	/ 81 (0.00%)		
subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0 Blood and lymphatic system disorders Anaemia subjects affected / exposed 0		1 / 79 (1.27%)	
subjects affected / exposed 0 occurrences (all) 0 Syncope vasovagal 0 subjects affected / exposed 0 occurrences (all) 0 Blood and lymphatic system disorders Anaemia subjects affected / exposed 0		1 / 79 (1.27%)	
Syncope vasovagal subjects affected / exposed occurrences (all) Blood and lymphatic system disorders Anaemia subjects affected / exposed 0	0		
subjects affected / exposed 0 occurrences (all) 0 Blood and lymphatic system disorders 0 Anaemia 0 subjects affected / exposed 0	-	1	
subjects affected / exposed 0 occurrences (all) 0 Blood and lymphatic system disorders 0 Anaemia 0 subjects affected / exposed 0			
Blood and lymphatic system disorders Anaemia subjects affected / exposed 0	/ 81 (0.00%)	1 / 79 (1.27%)	
Anaemia subjects affected / exposed 0	0	1	
Anaemia subjects affected / exposed 0			
	/ 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
Leukocytosis			
subjects affected / exposed 0	/ 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
Leukopenia			
	/ 81 (0.00%)	3 / 79 (3.80%)	
occurrences (all)	_		
Lymphadenitis	0	3	

subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Lymphadenopathy subjects affected / exposed	1 / 81 (1.23%)	0 / 79 (0.00%)	
occurrences (all)		0779(0.00%)	
	1	0	
Thrombocytopenia			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Vertigo			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Eye disorders			
Chorioretinal atrophy subjects affected / exposed	0 / 81 (0.00%)	1 / 70 (1 270/)	
occurrences (all)		1 / 79 (1.27%)	
	0	1	
Macular degeneration			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Papilloedema			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
	Ŭ	±	
Visual acuity reduced			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 81 (1.23%)	5 / 79 (6.33%)	
occurrences (all)	1	7	
Aphthous stomatitis			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
	Ť	-	
Constipation			

subjects affected / exposed	0 / 01 /0 000()	
	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences (all)	0	1
Dental caries		
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)
occurrences (all)	0	2
	-	
Diarrhoea		
subjects affected / exposed	0 / 81 (0.00%)	11 / 79 (13.92%)
occurrences (all)	0	17
Gastritis subjects affected / exposed	0 / 01 /0 000/)	1 (70 (1 270()
	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences (all)	0	1
Gastrointestinal motility disorder		
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences (all)	0	1
	Ŭ	
Nausea		
subjects affected / exposed	0 / 81 (0.00%)	3 / 79 (3.80%)
occurrences (all)	0	3
Odynophagia		
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences (all)	0	1
Vomiting		
subjects affected / exposed	1 / 81 (1.23%)	8 / 79 (10.13%)
occurrences (all)	1	
	L L	10
Hepatobiliary disorders		
Hypertransaminasaemia		
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences (all)	0	1
Liver diserter		
Liver disorder subjects affected / exposed	0 / 01 /0 000/)	1 / 70 / 1 070/)
	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences (all)	0	1
Skin and subcutaneous tissue disorders		
Acne		
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)
occurrences (all)	0	1
Cold sweat		

subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Dermatitis subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Dermatitis allergic subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Dry skin subjects affected / exposed occurrences (all)	1 / 81 (1.23%) 1	1 / 79 (1.27%) 1	
Eczema subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Ephelides subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Erythema subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Hyperhidrosis subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Ingrowing nail subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	2 / 79 (2.53%) 2	
Intertrigo subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Nail disorder subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Photodermatosis subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Pityriasis rosea			

Clinical trial results 2010-020925-42 v

subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Pruritus subjects affected / exposed			
	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Rash macular			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Scar pain			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
	, , , , , , , , , , , , , , , , , , ,	-	
Skin lesion			
subjects affected / exposed	1 / 81 (1.23%)	1 / 79 (1.27%)	
occurrences (all)	1	1	
Subcutaneous nodule			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Developed uning undiscurdence			
Renal and urinary disorders Proteinuria			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
· · ·	, , , , , , , , , , , , , , , , , , ,	_	
Endocrine disorders			
Hyperparathyroidism subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)			
	0	1	
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Croin pain			
Groin pain subjects affected / exposed	0 / 81 /0 000/)		
occurrences (all)	0 / 81 (0.00%)	1 / 79 (1.27%)	
	0	1	
Muscle spasms			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Pain in extremity			
	I	I	l

subjects affected / exposed	1 / 81 (1.23%)	2 / 79 (2.53%)	
occurrences (all)	1	3	
Sever's disease subjects affected / exposed	0 / 81 (0.00%)	1 / 70 (1 2704)	
occurrences (all)	0 / 81 (0.00%)	1 / 79 (1.27%)	
	0	1	
Tendinous contracture			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
Bronchitis subjects affected / exposed			
	0 / 81 (0.00%)	3 / 79 (3.80%)	
occurrences (all)	0	4	
Cystitis			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Cytomegalovirus infection subjects affected / exposed	0 (01 (0 00%)		
	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
Gastroenteritis			
subjects affected / exposed	0 / 81 (0.00%)	4 / 79 (5.06%)	
occurrences (all)	0	4	
Castrooptoritic viral			
Gastroenteritis viral subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)			
	0	2	
Nasopharyngitis			
subjects affected / exposed	0 / 81 (0.00%)	6 / 79 (7.59%)	
occurrences (all)	0	11	
Oral fungal infection			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
		+	
Oral herpes			
subjects affected / exposed	1 / 81 (1.23%)	4 / 79 (5.06%)	
occurrences (all)	1	4	

Oropharyngeal candidiasis subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0 / 81 (0.00%)	1	
Otitis externa			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Otitis media			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
Pharyngitis			
subjects affected / exposed	2 / 81 (2.47%)	8 / 79 (10.13%)	
occurrences (all)	2	12	
	2	12	
Pharyngitis streptococcal			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Purulent discharge			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	2	
Deenighter the stinfestion			
Respiratory tract infection subjects affected / exposed	0 / 81 (0.00%)	3 / 79 (3.80%)	
occurrences (all)			
	0	3	
Rhinitis			
subjects affected / exposed	1 / 81 (1.23%)	5 / 79 (6.33%)	
occurrences (all)	1	5	
Rotavirus infection			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Scarlet fever			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Tonsillitis			
subjects affected / exposed	0 / 81 (0.00%)	4 / 79 (5.06%)	
occurrences (all)	0	5	
Tracheitis			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)			
	0	1	

	1	1	1
Tracheobronchitis mycoplasmal			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Upper respiratory tract infection			
subjects affected / exposed	1 / 81 (1.23%)	5 / 79 (6.33%)	
occurrences (all)	1	7	
	±	,	
Urinary tract infection			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	2	
Viral infection			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	3	
	0	5	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	2	
Metabolism and nutrition disorders			
Anorexia			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Dehydration			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
	0	L	
Hyperglycaemia			
subjects affected / exposed	0 / 81 (0.00%)	2 / 79 (2.53%)	
occurrences (all)	0	3	
Hyperlipidaemia			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Hypokalaemia			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
	U	Ţ	
Hypomagnesaemia			
subjects affected / exposed	0 / 81 (0.00%)	1 / 79 (1.27%)	
occurrences (all)	0	1	
Iron deficiency			

subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	1 / 79 (1.27%) 1	
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 81 (0.00%) 0	2 / 79 (2.53%) 2	

Substantial protocol amendments (globally)

Date Amendment This amendment added trough levels of tacrolimus as an inclusion factor, and 22 April 2013 updated details of study administration. This amendment added the Part C extension to the study (particularly for Italy 04 November 2013 and Poland). This amendment added the Part C extension to the study (particularly for 23 April 2014 Germany and Czech Republic). The protocol was reissued to combine all the individual country-specific 01 December 2014 amendments into 1 combined Country Protocol Amendment for Italy, Poland, German and Czech Republic. This amendment added UK sites to Part C of the study to comply with a UK-28 June 2016 specific requirement. Notes:

Were there any global substantial amendments to the protocol? Yes

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported